ZELNORM
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jul 2002
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 17h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZELNORM is an oral tablet approved in 2002 for gastrointestinal motility disorders. The drug's mechanism of action and specific indications are not currently documented in available data. It is a small-molecule NDA product marketed by Alfasigma.
LOE Approaching
Product is in late-stage lifecycle with moderate competitive pressure (30%), suggesting defensive commercial positioning and possible team contraction planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ZELNORM currently has zero linked job opportunities, reflecting its mature and contracting portfolio status. This product is suited for professionals managing mature brands through LOE transition or seeking defensive sales strategy experience rather than growth-oriented career development.
Brand ManagerField Sales
Worked on ZELNORM at Alfasigma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.